Form 10-Q Baudax Bio, Inc. For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Baudax Bio Inc. (BXRX) PT Lowered to $2 at Oppenheimer
May 6, 2021 6:43 AM EDTOppenheimer analyst Leland Gershell lowered the price target on Baudax Bio Inc. (NASDAQ: BXRX) to $2.00 (from $3.00) while maintaining an Outperform rating.
The analyst commented, "Reported 1Q21 net sales of just $0.2M as COVID-19 continues to drag on Anjeso's launch, with P&T committee... More
